Aquestive Therapeutics (NASDAQ:AQST) Receives “Buy” Rating from HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 277.36% from the company’s current price.

A number of other equities research analysts have also issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective for the company. Lake Street Capital dropped their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Stock Performance

NASDAQ AQST opened at $2.65 on Monday. Aquestive Therapeutics has a one year low of $2.24 and a one year high of $6.23. The business has a fifty day moving average price of $3.09 and a 200 day moving average price of $4.10. The company has a market cap of $262.01 million, a P/E ratio of -5.89 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. As a group, sell-side analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Aquestive Therapeutics by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after acquiring an additional 3,821 shares during the last quarter. MetLife Investment Management LLC raised its position in Aquestive Therapeutics by 11.4% in the fourth quarter. MetLife Investment Management LLC now owns 40,221 shares of the company’s stock valued at $143,000 after purchasing an additional 4,125 shares during the period. Bank of Montreal Can lifted its stake in Aquestive Therapeutics by 10.1% during the fourth quarter. Bank of Montreal Can now owns 54,300 shares of the company’s stock worth $193,000 after purchasing an additional 4,999 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Aquestive Therapeutics by 3.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock worth $750,000 after buying an additional 7,129 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after buying an additional 7,347 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.